Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab (Darzalex) in multiple myeloma.

The first monoclonal antibodies have been approved for use in multiple myeloma. Daratumumab, a monoclonal antibody, binds to CD38, which is overexpressed by multiple myeloma cells.

The results seen with daratumumab have been quite striking, says Kumar. There have been 2 large phase III trials, both of which showed adding daratumumab to regularly used regimens improved progression-free survival.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Mayo Clinic

Cancer Centers

Partner

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.
 

Dr. Kumar Discusses Daratumumab in Multiple Myeloma